Submitted by: Submitted by HexaReport
Views: 10
Words: 963
Pages: 4
Category: Business and Industry
Date Submitted: 05/15/2016 11:58 PM
Hexa Reports
Market Research Reports and Insightful Company Profiles
COPD Therapeutics in Major Developed Market Size,
Share, Growth, Treatment, Analysis, Symptoms, Emerging
Trends and Opportunities to 2021
COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-inClass Products Offsets Sales Erosion of Leading Brands
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic
inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of
COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of
death in the world.
Browse Detail Report With TOC @
http://www.hexareports.com/report/copd-therapeutics-in-major-developed-markets/details
COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental
pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at
managing the symptoms associated with COPD, although none of the available therapies have been
shown to modify long-term disease progression.
Hexa Reports
Market Research Reports and Insightful Company Profiles
There are currently 203 products in active development, excluding four with an unknown stage of
development. Although many of the targets identified in the pipeline are well established in the
management of COPD, there are some novel, first-in-class targets. This reflects the growing
understanding of the underlying mechanisms that characterize the disease.
Scope
The COPD market has benefited from notable additions over recent years.
Which classes of drug dominate the market?
What additional benefits have newly approved therapies brought to market?
How do the leading marketed therapies compare clinically?
The pipeline contains a range of molecule types and molecular targets, including those that are well
established in COPD, and novel, first-in-class...